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Abstract
We have previously shown that peroxisome proliferator activating receptor ß/d (PPAR b/d is overexpressed in psoriasis.
PPAR b/d is not present in adult epidermis of mice. Targeted expression of PPAR b/d and activation by a selective synthetic
agonist is sufficient to induce an inflammatory skin disease resembling psoriasis. Several signalling pathways dysregulated
in psoriasis are replicated in this model, suggesting that PPAR b/d activation contributes to psoriasis pathogenesis. Thus,
inhibition of PPAR b/d might harbour therapeutical potential. Since PPAR b/d has pleiotropic functions in metabolism, skin-
targeted inhibition offer the potential of reducing systemic adverse effects. Here, we report that three selective PPAR b/
d antagonists, GSK0660, compound 3 h, and GSK3787 can be formulated for topical application to the skin and that their
skin concentration can be accurately quantified using ultra-high performance liquid chromatography (UPLC)/mass
spectrometry. These antagonists show efficacy in our transgenic mouse model in reducing psoriasis – like changes triggered
by activation of PPAR b/d. PPAR b/d antagonists GSK0660 and compound 3 do not exhibit systemic drug accumulation after
prolonged application to the skin, nor do they induce inflammatory or irritant changes. Significantly, the irreversible PPAR b/
d antagonist (GSK3787) retains efficacy when applied topically only three times per week which could be of practical clinical
usefulness. Our data suggest that topical inhibition of PPAR b/d to treat psoriasis may warrant further exploration.
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Introduction
One prominent clinical aspect of psoriasis is the clinical overlap
with metabolic syndrome [1] and its association with increased
body mass index [2], indicative of overlapping signalling pathways
in psoriasis and other disorders of metabolism and chronic
inflammation. Peroxisome proliferator activated receptors (PPAR)
beta/delta (PPAR b/d), one of three PPAR isoforms, is a key
regulator of glucose and lipid metabolism [3]. In psoriasis plaques,
PPAR b/d is up-regulated, while the other PPAR isoforms, alpha,
and gamma, are down-regulated [4]. PPARs act as regulators of
transcription, being activated by lipid ligands to bind cognate cis-
acting elements in target promoters upon heterodimerization with
retinoic x receptor (RXR) alpha.
In the skin, PPAR b/d is involved in keratinocyte differentiation
and the wound response [5]. It is induced (among other factors) by
TNFa [6,7], stimulates proliferation and blocks apoptosis in
keratinocytes [8], and induces angiogenesis [9]. In psoriasis lesions,
PPAR b/d exhibits prominent nuclear localisation in the upper
spinous layer [4]. While not expressed in adult inter-follicular skin
in mice, its activation in the spinous layer is sufficient to elicit an
inflammatory skin disease harbouring major elements of psoriasis.
Thus, PPAR b/d transgenic mice exhibit psoriasis-typical
immunological changes, STAT3 activation, as well as psoriasis –
specific gene dysregulation [4]. Moreover, the gene dysregulation
profile induced by epidermal PPAR b/d activation significantly
overlaps with that characteristic of psoriasis, including faithful
replication of well recognised functional clusters such as the entire
Il1-module or the cholesterol biosynthesis program, suggesting
that the subsets of genes dysregulated by PPAR b/d activation are
also regulated by PPAR b/d in psoriasis. Collectively, these
observations indicate that PPAR b/d signalling may contribute to
the overlap between psoriasis and metabolic, as well as cardio-
vascular disease [10], since it is up-regulated in chronic in-
flammation and regulated by caloric intake [11,12]. TNFa,
obesity, chronic inflammation, and dyslipidemia all may increase
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and/or activation. Taken together, several lines of evidence
suggest that PPAR b/d activation contributes to psoriasis
pathogenesis and that blocking its activation may reduce disease
activity.
In light of the complex role PPAR b/d exerts in metabolism,
a topical ointment approach would seem an attractive targeting
strategy in order to minimise the chance of adverse systemic
effects. However, isoform – selective PPAR b/d antagonists have
only recently become available [13–16], and have not yet been
evaluated for their activity in vivo via transdermal application. A
major limitation in assessing the latter aspect is the availability of
a validated and robust method to quantify the active compounds
in the skin.
Here we describe the formulation of three selective PPAR b/
d antagonist into ointments and the quantification of their
concentration in murine skin. In order to assess their ability to
inhibit PPAR b/d in vivo, we employ a previously described
transgenic model [4]. In this model, human PPAR b/d is
constitutively expressed in sebaceous glands. Addition of the
PPAR b/d selective synthetic agonist GW501516 triggers both
epidermis-specific transcriptional induction and ligand-mediated
activation of PPAR b/d, causing the development of an
inflammatory skin disease with similarity to psoriasis. We show
that PPAR b/d antagonists in ointment formulation can deliver
pharmacologically active concentrations in the skin, show very
little systemic absorption, that prolonged administration does not
cause inflammatory changes, and that they inhibit PPAR b/
d mediated psoriasis-like pathogenesis in vivo.
Results
Choice of PPAR b/d selective antagonists
PPAR b/d isoform-selective antagonists have only recently been
described [13–17]. For the present work we used the first one to be
reported, GSK0660, based on high antagonist potential, high
affinity, its documented anti-inflammatory effect [18], and
a reported lack of bioavailability upon systemic administration
[17], thus potentially increasing its usefulness as a skin specific
targeting compound. In order to ensure that any effects seen in vivo
are indeed due to PPAR b/d antagonism and not caused by off-
target effects related to the chemical structure of GSK0660, we
also included an alternative antagonist, compound 3 h [13], in
a subset of experiments. Compound 3 h was chosen because of its
low reported Ki (11 nM), high competitive antagonist potency, as
well as lack of activity on other PPAR isoforms [13], The structure
and key properties of these antagonists are shown in figure 1. An
alternative reported compound appears to be less isoform selective
[14]. Finally, one additional PPAR b/d antagonist irreversibly
inactivates the receptor by forming a covalent bond (GSK3787)
[15,16]. This compound was included to address the feasibility of
achieving treatment effects with less frequent dosing.
Ointment formulation
A variety of vehicles, additives, and procedures were screened as
vehicles for the incorporation for GSK0660 and compound 3 h.
These included drug incorporation into liquified vehicle at 70uC,
pre-disolvement in DMSO, ethanol, isopropanol, polyethyene
glycol 300, and olive oil followed by vehicle incorporation, as well
as a variety of vehicles (liquid paraffin, Hydromol ointment,
aqueous ointment BP). Drug solubility was assessed using a pre-
viously reported method relying on the absence of crystals
detectable by polarised microscopy [19]. It was furthermore found
that GSK0660 underwent a visible colour change from yellow to
green after storage at room temperature and light exposure,
indicating instability possibly due to oxidation, which would be
predicted given its chemical structure (fig. 1). Thus, alpha-
tocopherol was added to GSK0660 preparations to increase
stability. The optimised formulation of both compounds is detailed
in Methods, was found to be devoid of drug crystals up to 2% (w/
w) for both compounds, and exhibited functional activity, as
described below.
Lack of systemic absorption of PPAR b/d antagonists
Targeting PPAR b/d is potentially fraught with serious adverse
effects, since PPAR b/d impacts on a wide variety of metabolic
processes. We developed a robust quantitative assay based on
ULPC/mass spectrometry to allow quantification of GSK0660, as
well as compound 3 h, in skin samples subjected to ointment
treatment (see Methods). Using this technology, we investigated
whether the topical application of PPAR b/d antagonists to
murine skin results in significant systemic drug accumulation. As
shown in figure 2, peak systemic concentration of GSK0660,
measured 1 h after topical application, remained well below
reported EC50 and IC50 values while that of compound 3 h was
slightly above the in vitro determined EC50 value at this time
point (figure 1). The total amount of detectable compound was less
than 0.01% of total drug applied. By contrast, the PPAR b/
d agonist used in this study, GW501516, exhibited 100-fold higher
systemic absorption, achieving peak serum concentrations of
400 nM at 1 h post application, despite being concentrated 10-
fold less (0.1% ointment). This concentration of GW501516 is well
within the range of its expected pharmacological activity [20].
Pharmacokinetic measurements of GSK0660 in blood for 24 h
after drug application showed no evidence of drug accumulation.
Systemic concentration remained well below the predictive active
concentration, and amounted to less than 0.01% of total drug
applied being detectable (figure 2b). By contrast, the same amount
of drug was able to achieve a high local concentration in skin,
exhibiting a half life of approximately. 90 min (figure 3). These
data demonstrate that topical administration of PPAR b/
d antagonists achieves skin specific drug application, thereby
avoiding potential hazards associated with PPAR b/d inhibition in
other organ systems. Of note, since application of even 10-fold less
concentrated agonist ointment (GW501516) achieves significant
serum levels, only partial biological activity would be expected for
the antagonists in this in vivo model.
Lack of inflammatory changes in skin after topical
application of PPAR b/d antagonists
We next determined the local concentrations in skin at steady
state after prolonged topical application. GSK0660 or compound
3 h were administered to shaven dorsal skin twice daily for seven
days. Skin samples were then extracted and analysed by mass
spectrometry for concentration determination as well as processed
for histology. As shown in figure 4a, both compounds achieved
high local concentrations even for the lower dose used (0.2%),
suggesting active concentrations are present locally for prolonged
time periods at the twice-daily dosing regimen, assuming a half life
of approximately. 90 min (cf. fig. 2b). Under these conditions,
neither antagonist produced notable epidermal hyperplasia (fig. 4,
panels on right). The number of dermal nuclei counted per high
power field was also unchanged as compared to vehicle-only
treated skin (not shown). This was also found for the alternative
PPAR b/d antagonist GSK3787 (figure 4b). Infrequently, we
noted apoptotic epidermal keratinocytes (inset, middle row of
H&E sections). Since these cells were also found in transgenic
PPAR b/d mice treated with the agonist only (figure S1), the exact
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PLoS ONE | www.plosone.org 2 May 2012 | Volume 7 | Issue 5 | e37097Figure 1. PPAR b/d selective antagonists used in this study. Chemical structures and in vitro pharmacodynamic data shown are taken from the
references listed. The structure of the PPAR b/d selective agonist GW501516 used in this study is given for comparison.
doi:10.1371/journal.pone.0037097.g001
Figure 2. Low systemic absorption of topically applied PPAR b/d antagonists. A. Peak blood concentrations of PPAR b/d agonist GW501516,
and antagonists GSK0660 and compound 3 h, respectively, at 1 h after topical application to skin. Left: Amount of drugs detected in systemic
circulation, expressed as fraction of total amount applied, was calculated as detailed in methods. Right: Drug concentration expressed as molar
concentration. B. GSK0660 concentration in blood (left) and total amount of circulating drug as fraction of amount applied (right, calculated as
described in Methods) at the indicated time points after drug application. The horizontal dashed line represents the reported IC50 for GSK0660 acting
on PPAR b/d reported previously (300 nmol/L). Data shown represent average 6 s.d. of n=3 mice per data point.
doi:10.1371/journal.pone.0037097.g002
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effect of the antagonist creams.
Inhibition of PPAR b/d mediated psoriasis-like skin
disease
We next sought to determine whether skin-targeted adminis-
tration of PPAR b/d antagonists would be sufficient to inhibit
PPAR b/d agonist-driven development of skin disease. In a first set
of experiments we applied both the agonist (GW501516), as well as
either antagonist (GSK0660 or compound 3 h) directly to the skin
in order to minimise pharmacokinetic differences associated with
alternative routes of drug administration (i.e. oral verus trans-
dermal) between the competing chemicals. GW501516 was
formulated as an 0.1% ointment and applied five times per week
to shaved dorsal skin of PPAR b/d transgenic mice. This agonist
concentration was chosen because (a) lower agonist concentrations
had resulted in significantly prolonged time-to-onset of the
phenotype in pilot experiments and (b) higher concentrations
would not achieve a molar excess of the antagonist (using 1%
ointments for the antagonists), which was important since the
available in vitro data suggested that competitive antagonism at the
receptor might not be achieved at equimolar concentrations of
both agonist and antagonist. Antagonist-containing ointments
were applied once per day six hours apart from the agonist in
order to minimise any influence of penetration of both chemicals.
Mice receiving GW501516 ointment and vehicle-only served as
positive control, while mice receiving only vehicle ointments for
both the antagonist as well as the agonist served as negative
control. After 20 days of treatment, mice were sacrificed and skin
samples processed for H&E histology. As shown in figure 5, both
GSK0660 and compound 3 h, respectively, significantly attenu-
ated the psoriasis – like epidermal hyperplasia induced by
GW501516-mediated activation of PPAR b/d. These data suggest
that bioavailability of both antagonists is sufficient upon trans-
dermal delivery to compete for agonist-binding to the receptor in
vivo. MS-based quantification of GSK0660 in PPAR b/d mice
12 h after the last cream application showed a concentration of 48
6 18 ng/g of tissue while no GSK was detectable in blood
(threshold of detection: 25 nmol/l), showing that penetration
through inflamed skin with altered permeability properties does
not lead to increased local or systemic accumulation of GSK0660
after prolonged administration.
We next investigated whether PPAR b/d antagonists are able to
reverse established skin disease. For this experiment, we admin-
istered the agonist GW501516 orally in order to allow twice –
daily topical application of the antagonist without possible
interference with drug penetration. We thus induced skin disease
by oral dosing of GW501516, using a modified dosing regimen to
that previously described as detailed in Methods. Three weeks
after initiation of treatment with antagonists, mice were sacrificed
and skin samples analysed. As shown in figure 6a, both PPAR b/
d antagonists were able to partially reverse epidermal hyperplasia.
The influx of both CD4+ and CD8+ T lymphocyte subsets was
also reduced, as shown in figure 6b. (cell numbers were too low to
allow quantification of IL17+ T cell subsets). Finally, we also
quantified expression levels of genes previously shown to be
induced by PPAR b/d in the skin [21], HB-EGF, a direct target
gene of PPAR b/d [22], as well as two strongly induced indirect
Figure 3. Half – life of GSK0660 after topical application to
skin. 42 mg of GSK0660 ointment was applied to dorsal skin of C57Bl/
6j wild type mice. Mice were sacrificed at the time after drug application
indicated in the figure and drug concentration determined by mass
spectrometry, as detailed in Methods. Data shown represent average 6
s.d. of n=3 mice per data point.
doi:10.1371/journal.pone.0037097.g003
Figure 4. Absence of inflammatory changes induced by PPAR b/d antagonists in skin after topical application. (a) C57Bl/6j wild type
mice were treated with ointments containing GSK0660 or compound 3 h applied twice daily to shaved dorsal skin for one week. Mice were sacrificed
1 h after the last ointment application and skin tissue processed for H&E based histology and mass spectrometry, as described in Methods. Data
shown represent average 6 s.d. of n=3 mice per data point (left) treated with GSK (blue columns) or compound 3 h (red). Representative histology
sections of all treated mice are shown on right. The inset in the middle panel shows a section of GSK0660-treated epidermis showing apoptotic
looking cells (marked by red arrow head). Horizontal bar represents 5 mm. (b) Representative H&E sections of C57Bl/6j wild type mice treated for one
week with either GSK0660 (top) or GSK3787 (bottom). Red arrow-heads denoting apoptotic looking cells.
doi:10.1371/journal.pone.0037097.g004
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upregulation of both HB-EGF and LCE3e was partially reversed
by treatment with both PPAR b/d antagonists, although this
reached statistical significance only for LCE3e. Reversal of IL1b
expression was only observed using the ointment containing
GSK0660. Taken together, these data show that transdermal
application of PPAR b/d antagonists is able to reverse established
psoriasis-like disease in PPAR b/d transgenic mice.
Reduced-frequency PPAR b/d antagonist ointment
application may be feasible using an irreversible
antagonist
The half-life of GSK0660 suggested that the frequency of cream
application might be limiting for treatment efficacy. Indeed, we
found that twice-daily ointment application was required for full
efficacy (fig. S1). The PPAR b/d antagonist GSK3787 has been
shown to covalently bind to its target, causing permanent
inactivation. Since this property may be extremely useful clinically
by offering the potential of less frequent cream application, we
explored the effect of GSK3787 in the present system. As shown in
figure 7, treatment using GSK3787-containing ointment proved to
be as effective as GSK0660 in preventing epidermal hyperplasia
(fig. 7a), as well as reducing the amount of dermal infiltrate (fig. 7b),
even when applied only 36 per week. The tissue level of
unmodified GSK3787 in lesional skin (GSK3787 covalently
attached to PPAR b/d could not be quantified) did not differ
significantly between the three treatment groups 16 h after the
final application and was found overall slightly higher than that
found for GSK0660 (240 6 116 nmol/g of tissue vs. 91 6
21 nmol/g for GSK0660), indicating that slightly better tissue
penetration may contribute to treatment efficacy. Efficacy of
GSK3787 at reduced frequency application was further confirmed
in an additional experiment testing the effect of twice-daily versus
three times weekly application of GSK3787 (figure 8). This
experiment also verified suppression of the PPAR b/d target genes
LCE3f, IL1-beta, and HBEGF (fig. 8b). Quantification of
GSK3787 in blood of at the end of the experiment (16 h after
last cream application) yielded a concentration of 445 6
429 nmol/l, suggesting higher systemic resorption than
GSK0660. Systemic resorption appears to be facilitated through
inflamed skin since GSK3787 blood concentration in healthy mice
after 20 days of twice-daily treatment was only 50.2 6 25.7 nmol/
l (n=3 mice). Nonetheless, the therapeutic activity is mediated
locally, since efficacy was limited to the area of cream application
(figure S2). Taken together, the data show that irreversible
covalent modification of PPAR b/d may harbour the potential of
less frequent ointment application.
Discussion
The treatment of psoriasis with PPAR ligands has been
previously explored. Since PPAR b/d may act as a direct
antagonist to PPARc [23] and PPARc activation inhibits STAT3
[24], activation of PPARc unsurprisingly has a mild inhibitory
effect on psoriasis [25,26]. Systemic administration of the PPARc
agonist pioglitazone to psoriasis arthritis patients, while showing
signs of anti-arthritic acitivity, produced no marked reduction of
PASI scores [27]. Topical application of the preferential PPARc
agonist rosiglitazone and the pan-PPAR agonist tetradecylthioa-
cetic acid (TTA) showed no effect [26], possibly since concurrent
activation of both PPARc and PPARß/d produces mutually
neutralising effects (contrary to a commonly held view, rosiglita-
zone not only activates PPARc but can also activate PPAR b/
d [18]). As selective PPAR b/d antagonists have only recently
become available, they have not yet been tested clinically. Our
current data clearly support the notion that these may act anti-
inflammatory in psoriasis.
The observation of therapeutic efficacy using three alternative
PPAR b/d antagonists confirms that the effects seen are mediated
through PPAR b/d binding rather than ideosyncratic off-target
effects. The results presented here show some variation between
the compounds tested (figs 5, 6b,c, 7, 8). GSK3787 stands out both
by allowing reduced frequency application, as well as by exhbiting
appreciable systemic concentrations in blood after prolonged
application. More detailed kinetic follow-up studies on human skin
will be required to ascertain whether this finding represents
a potential safety issue. In this regard, the establishment of an
ultra-sensitive quantitative mass-spectrometry assay will be in-
strumental.
The effect of the PPAR b/d antagonists on the phenotype in the
present model were only partial. Thus, it is possible that alternative
PPAR b/d antagonists would be more potent. More likely,
however, limited efficacy is inherent to the model used here, as the
Figure 5. Prevention of epidermal hyperplasia by transdermal application of selective PPAR b/d antagonists. Both the PPAR b/d agonist
GW501516 (GW) and the antagonists GSK0660 (GSK) or compound 3 h were applied topically to the skin, as described in the text. Left: representative
H&E-stained paraffin-sections of dorsal skin from PPAR b/d transgenic mice after treatment with ointments containing the indicated drugs for twenty
days, as detailed in Methods. Horizontal bar represents 5 mm. Right: quantification of H&E-based epidermal thickness observed in n=4 mice per
group, performed as detailed in Methods. * p,0.05 in a two-sided independent t-test.
doi:10.1371/journal.pone.0037097.g005
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GW501516 to induce and maintain the phenotype. In psoriasis
patients, such a synthetic ligand is not at work. Conversely, it is
worth pointing out that oral administration of GW501516,
currently explored to treat metabolic syndrome, may trigger
psoriasis flares in susceptible individuals. Endogenous activation of
PPAR b/d occurs by unknown natural ligand(s). A variety of
arachidonic acid species have been described as candidates. One
very plausible candidate would be 12-(R)-HETE which accumu-
lates in psoriasis [28], particularly because the enzyme catalysing
Figure 6. Reversal of psoriasis-like skin disease in PPAR b/d mice by PPAR b/d antagonists. Skin disease was induced by systemic oral
administration of the PPAR b/d agonist GW501516. (Control mice received standard chow). Subsequently, GW501516 dose was lowered to allow
maintenance of phenotype as described in the text and mice were treated twice daily with either vehicle only (GW501516 group) or antagonist-
containing ointments, as indicated. A. Reversal of epidermal hyperplasia, performed as described in the legend for figure 5. Horizontal bar represents
5 mm. B. Reduction of T cell infiltration. Skin samples of the treated skin regions were processed and stained for FACS analysis as described in
Methods. Scatter plots shown on left show representative data, column diagrams on right show quantification of FACS data in n=4 mice per group.
The scatter plot shown at the bottom indicates the lympocyte gate used for quantification of CD4/CD8 cells, as previously described [21]. C.
Quantification of target genes previously been shown to be induced in PPAR b/d transgenic mice by qPCR, as detailed in Methods. * p,0.05 in a two-
sided independent t-test.
doi:10.1371/journal.pone.0037097.g006
Figure 7. Control of PPAR b/d – mediated skin disease using reduced-frequency application of ointment containing an irreversible
PPAR b/d antagonist. Skin disease in PPAR b/d transgenic mice was induced by i.p. injection of the agonist GW501516. Additionally, mice were
shaved on their abdomen and were treated with vehicle-ointment or ointment containing either GSK0660 (twice daily) or GSK3787 at the indicated
frequencies. Red arrow denotes apoptotic cells noted in the GW-only treatment group. A. Top: Representative H&E stains from 3 different mice in
each treatment group. Horizontal bar represents 5 mm. Bottom: Quantification of epidermal thickness (p,0.01 in all treatment groups vs. GW-only).
B. Quantification of dermal infiltrate. Data shown represent average 6 s.d. of five mice per group.
doi:10.1371/journal.pone.0037097.g007
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localised to the same sub-epidermal compartment as PPAR b/d,
i.e. the upper spinous layer. However, none of the naturally
occurring PPAR b/d ligands display a potency comparable to
GW501516. Thus, it is quite possible that application of PPAR b/
d antagonists may be more efficient than in the transgenic model.
The role of PPAR b/d in inflammation is complex. On the one
hand, some reports suggest anti-inflammatory properties (e.g.
[30]). However, PPAR b/d deficient mice do not show phenotypes
indicative of increased systemic inflammatory signalling. On the
other hand, PPAR b/d activation causes pro-inflammatory
changes in a number of systems, including IL-8 and IL1b
induction in macrophages [18], and massive inflammatory
changes in gastric tumors caused by PPAR b/d activation,
including IL1, IL6, IL24 induction [31]. When activated in the
epidermis in mice, PPAR b/d also induces the complete IL-1
signalling ‘‘module’’ characteristic of psoriasis including pro-
inflammatory (IL1b, IL1F8), as well as anti-inflammatory
cytokines (IL-1F5, IL1RA). As noted by others, the effect of
PPAR b/d activation on inflammatory signalling appears de-
pendent on the tissue studied [31]. In the epidermis of PPAR b/
d transgenic mice harbouring PPAR b/d expression comparable
to human epidermis, it clearly acts pro-inflammatory [4]. The
present data provide no evidence for pro-inflammatory changes
caused by PPAR b/d inhibition, confirming a previous report that
failed to identify inflammatory changes upon systemic adminis-
tration of a PPAR b/d antagonist in vivo [16].
The obvious limitation of the current results is that only one
model is being tested. Although widening the scope two alternative
models may be desirable, this is hampered by practical considera-
tions. The SCID model, hailed as ‘‘gold standard’’ by many
authors, has inherent limitations: first, each data point generated
Figure 8. Effect of GSK3787 on PPAR b/d -mediated skin disease applied either twice daily or three times per week (once per day). A.
Left: representative H&E stains from 3 different mice in each treatment group. Horizontal bar represents 5 mm. Right: Quantification of epidermal
thickness and dermal nuclei, respectively. * p,0.05 vs. GW501516 only. B. Q-PCR based quantification of the PPAR b/d target genes LCE3f, IL1b, and
HBEGF, as in figure 6c. Data shown represent n=5 mice per treatment group.
doi:10.1371/journal.pone.0037097.g008
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robust enough to withstand the mechanical challenge of cream
treatment. It may be feasible to use this model at least to test
systemic application of PPAR b/d antagonist which is currently
being explored. Of many other models propagated [32], all are
limited in their modelling capacity of psoriasis for a variety of
reasons [33], thereby curtailing predictive power for the human
system. In addition to psoriasis-specific limitations, murine skin
harbours penetration properties quite different from human skin.
Thus, further preclinical testing will benefit most from porcine skin
for penetration aspects as well as preclinical testing of GMP-grade
products on human skin. Thus, short term ex-vivo treatment of
human skin obtained from surgical procedures can be used not
only to further investigative the presence of keratinocyte apoptosis
but also the formation of PPAR b/d -GSK3787 adducts.
In conclusion, we here show that selective antagonists of PPAR
b/d can be transdermally delivered, achieve pharmacologically
active concentrations, and are able to antagonise PPAR b/
d activation by a potent agonist delivered orally, thereby partially
inhibiting the development of an inflammatory skin disease. Their
potential to treat psoriasis or related conditions remains to be
explored in clinical trials.
Methods
Ointment formulation
All PPAR b/d antagonists were custom-synthesized by AF-
Chempharm (UK). Purity was .98% (GSK0660) and 97% (3 h,
GSK3787), respectively, as determined by mass spectrometry.
GSK0660 and alpha-tocopherol were predissolved in DMSO,
vortexed, and incorporated into Hydromol ointment at room
temperature using a melamin bowl and pestle to yield final
concentrations of 0.5% (w/w) GSK0660, 0.1% (w/w) alpha-
tocopherol, and 5% (w/w) of DMSO, respectively. Compound 3 h
was pre-dissolved in DMSO, left at room temperature for 20 min
at low agitation and then incorporated into Hydromol ointment
using a melamin bowl to yield final concentrations of 0.5% (w/w)
3 h, and 5% (w/w) of DMSO, respectively. GSK3787 ointment
(containing 0.5% final w/w) was made exactly analogous to
GSK0660 ointment. Vehicle-only contro ointment was prepared
exactly as GSK0660 ointment while omitting the chemical itself.
Ointments were stored in airtight containers at 4uC in the dark
and made fresh once a week.
Chow formulation
All GW chow concentrations were made up by diluting a stock
of powdered chow containing 0.3% GW501516 with standard
powdered chow and by mixing thoroughly. GW chow was stored
at 4uC and replaced approx. once a week.
Evaluation of peak serum concentration and GSK0660
pharmacokinetics
GSK0660 ointment was prepared fresh, loaded into a 1 mL
syringe allowing variability of drug to remain less than 10% CV,
and 42 6 5 mg of ointment was applied to 262 cm of shaven
dorsal skin of C57Bl/6j wild type mice. Mice were sacrificed 1 h
post application in a CO2 chamber (for peak blood concentrations
determined for GW501516, GSK0660, compound 3 h), or at the
time points indicated in the figure. 50 mL of cardiac blood were
diluted 1:2 (v:v) with milipore water and snap frozen immediately.
Previously treated skin segments were shaved, tape-stripped three
times to remove residual hair and non-absorbed ointment on the
surface, and then snap frozen in liquid nitrogen. Frozen skin was
ground and ten times the volume of methanol-water (1:1 v/v) was
added per weight unit of skin. A minimum of 20 mg of skin was
used per each sample. Samples were homogenized with a Covaris
S2 acoustic homogeniser. For both cardiac blood and skin
homogenate, proteins were precipitated by adding 3 volumes of
acetonitrile containing a suitable internal standard. All samples
were then centrifuged for 10 minutes at 2800 rpm before transfer
of 200 mL of supernatant into a 96 well plate and 100 mL of milliQ
water added. Calibration curves were constructed in either
untreated homogenised skin or blood to cover at least 3 orders
of magnitude (1–2000 ng/mL) and extracted as for aforemen-
tioned study samples. All cardiac blood, skin samples and
standards were then investigated by mass spectrometry as
described below. For calculation of total blood volume, mice were
weighed and an average blood volume of 7% (mL/g) of body mass
was assumed.
UPLC and mass spectrometry
An Acquity ultra high performance liquid chromatography
(UPLC) system; consisting of an autosampler, the Acquity UPLC
Sample Manager with Sample Organiser, a pump, the Acquity
UPLC Binary Solvent Manager, an in-built column oven, a UV
detector, the Acquity UPLC Photo Diode Array) and a Quattro
Premier XE triple quadrupole mass spectrometer (Waters, UK).
Masslynx version.4.1 data acquisition software, was used in the
determination of GW501516, GSK0660, compound 3 h, and
GSK3787 in blood and skin samples using positive electrospray
ionization. The analytical column was an Acquity UPLC BEH
C18, 2.1 mm i.d. 650 mm length, 1.7 mm particle size (Waters,
UK). No guard column was used, but a vanguard 0.2uC.
Mobile phase A was Milli-Q reverse phase de-ionised water
with formic acid (0.1%, v:v), mobile phase B was acetonitrile with
formic acid (0.1%, v:v). Mobile phase was delivered at a flow rate
of 0.6 mL/min. Gradient elution was used, for MRM analysis
mobile phase B was set initially at 5% for 0.5 min was then
linearily increased to 95% over 1.5 min and kept at 95% for
0.5 min. Finally mobile phase B was returned to 5% over 0.1 min
and maintained at this composition for 0.4 min. Total run time
3 min.
The entire flow was introduced into the Mass spectrometer. The
autosampler was set at 4uC and an injection voloume of 5 mL was
used (partial loop). Mass spectrometric detection was performed
using Multiple reaction monitoring (MRM) using the following
mass transitions; GW501516, m/z 454.21 to 257.13, cone voltage
(CV) 15 V, collision energy (CE) 33 V; GSK0660, m/z 419.20 to
214.17, (CV) 25 V, (CE) 19 V; compound 3 h, m/z 504.33 to
297.19 (CV) 5 V, (CE) 12 V. Desolvation temperature was 500uC
and gas flow 1000 L/h (Nitrogen). An in-house proprietary
internal standard was used for determination of all 3 analytes.
Example chromatograms of standard, QC, Sample and blank are
presented as well as the calibration curves are shown for
GW501516 (Methods S1), as well as GSK0660 and compound
3H (Methods S2).
Animal handling and dosing
All animal studies reported here were subject to approval of
Tayside Research Ethics Committee, and are conducted in
accordance with UK Home Office procedures (project licence
60/3800, licence holder JF). Breeding of PPAR b/d transgenic
mice and genotyping were all carried out as described previously
[21]. For the experiments described in Figure 6, GW501516 was
administered at a concentration 0.002% in powder chow for 48 h
to induce transgene induction, followed by reducing concentration
to 0.0025%. Application of antagonists in ointment was initiated
after 20 days and continued twice daily for 3 weeks. For the
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PLoS ONE | www.plosone.org 9 May 2012 | Volume 7 | Issue 5 | e37097experiment described in figure 7, skin disease was induced by 36
weekly i.p. injection of 150 mg GW501516 dissolved in 5%
DMSO/PEG 700 after additional pilot studies had shown that this
route of dosing allowed for tighter control of GW501516 serum
concentration, reduced inter-individual variability in phenotype
severity, as well as reduced overall consumption of GW501516.
Quantification of acanthosis
Mice were sacrificed, skin samples obtained and processed for
H&E based histology as described [21]. All samples were
photographed at 2006 magnification. Epidermal thickness was
measured for all slides by a blinded observer at perpendicular
angle to the basement membrane. The absence of variable planes
of tissue sectioning as a confounder for apparent epidermal
thickness was ruled out by verifying visible perpendicular insertion
of hair follicles into the epidermis. For each sample, two
measurements were taken in two separately photographed non-
adjacent sections of the H&E stained skin sample.
Flow-cytometry of skin-resident T cells
Skin was shaven and cut to appr. 10–15 mm
3 size using scissors.
Skin-associated fatty and vascular tissue was thoroughly scraped
off using a scalpel to reduce the presence of T cells located in blood
and lymphatic vessels. Samples were incubated for 30 min at 37uC
in 2 mL of RPMI incl. Pen/Strep and 10% FCS, 2 mg/mL
collagenase IV (Roche, cat-nr. 110880855001) and 1.1 U/mL
dispase I (Roche, cat-nr. 04942086001) reconstituted in HBSS.
Skin was washed with PBS over a cell strainer (100 mm Falcon)
and subsequently incubated in 2 mL of RPMI incl. Pen/Strep and
10% FCS, 0.5 mg/mL PMA, 0.5 mg/mL ionomycin for 2 h. In
modification of the previously described procedure 0.61 U/mLo f
DNase (Invitrogen) was to minimise clumping of cells. This
addition significantly increased the yield of cells. The following
antibodies served for surface staining: CD4-FITC (BD, Clone
RM4-4), CD8-PerCP-Cy5.5b (BD, 53–6.7). Flow cytometry
analysis was performed using a BD LSR Fortessa flow cytometer
and data was analysed by means of BD FACSDiva Software.
Real-time PCR
Skin was processed by removing subcutaneous tissue and small
skin pieces were snap frozen in liquid nitrogen. Frozen skin was
ground and RNA was extracted using the NucleoSpin RNA/
Protein kit from Macherey-Nagel. cDNA synthesis was done with
the SuperScript Vilo cDNA synthesis kit from Invitrogen. Gene
expression levels were quantified using TaqMan-based real-time
PCR using Assays-on-Demand kits obtained from Applied
biosystems according to the manufacturer’s instruction and
quantification performed as calibrated to the internal housekeep-
ing gene GAPDH (LCE3f: Mm02605425, Il1b: Mm01336189,
Hb-EGF: Mm00439305).
Supporting Information
Methods S1 Example chromatograms of standard, QC, Sample
and blank are presented as well as the calibration curves for
GW501516.
(DOC)
Methods S2 Example chromatograms of standard, QC, Sample
and blank are presented as well as the calibration curves for
GSK0660 and compound 3H.
(DOC)
Figure S1 Inhibition of PPAR b/d -induced skin disease by
topically administered antagonist GSK0660 requires twice-daily
application for full efficacy. PPAR b/d – transgenic mice were
dosed with GW501516 by 36weekly i.p. injection of the agonist
GW501516 as detailed in Methods, and additionally treated with
vehicle or GSK0660 ointment once or twice daily. (a) Represen-
tative H&E stains for each of the treatment groups (left) as well as
quantification of acanthosis, as well as dermal infiltrate (cells per
high power field, right). Red arrow head denotes apoptotic cell
observed in the GW-only group. (b) Expression analysis of target
genes known to be induced in lesional skin of PPAR b/d mice, as
analysed by qPCR. Data shown represent average 6 s.d. of four
individual mice per group. * p,0.01 in a two-sided t-test.
(TIF)
Figure S2 Limited range of PPAR b/d antagonist ointment
activity. H&E samples from the abdominal area treated with
antagonist ointment were obtained in the experiment described in
figure 7 and images obtained from the treated area (left) as well as
the edge of the treated area (right), indicating that the effect of
treatment is limited to the area treated.
(TIF)
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